Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles, 32834-32835 [2017-14996]
Download as PDF
32834
Federal Register / Vol. 82, No. 136 / Tuesday, July 18, 2017 / Notices
research before making important
decisions such as adopting new policies
and allocating or redirecting significant
resources to support these policies.
This survey has been repeated
approximately every 3 to 5 years over
the course of the past 3 decades for the
purpose of tracking changes and trends
in public opinions and consumer
behavior, with some new questions
added or omitted or partially modified
in each iteration in response to
emerging and current events or issues.
In the next 3 years, we plan to field this
survey two to three times. We will use
the information from the Health and
Diet Survey to evaluate and develop
strategies and programs to encourage
and help consumers adopt healthy diets
and lifestyles. The information will also
help FDA evaluate and track consumer
awareness and behavior as outcome
measures of their achievement in
improving public health.
Description of Respondents: The
respondents are adults, age 18 and
older, drawn from the 50 States and the
District of Columbia. Participation will
be voluntary.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
Cognitive interview screener ....................................
Cognitive interview ...................................................
Pretest screener .......................................................
Pretest ......................................................................
Survey screener .......................................................
Survey ......................................................................
100
18
2,000
200
40,000
4,000
1
1
1
1
1
1
100
18
2,000
200
40,000
4,000
0.08 (5 minutes) ........
1 ................................
0.033 (2 minutes) ......
0.25 (15 minutes) ......
0.033 (2 minutes) ......
0.25 (15 minutes) ......
8
18
66
50
1,320
1,000
Total ..................................................................
........................
........................
........................
....................................
2,462
sradovich on DSK3GMQ082PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We base our estimate of the number
of respondents and the average burden
per response on our experience with
previous Health and Diet Surveys and
we estimate that the burden for this
information collection has increased by
580 hours (from 1,882 to 2,462 hours)
since the last OMB approval. The
increase is due to an expected increase
in the number of participants
completing the survey screener (from
30,000 to 40,000 participants) and
number of participants taking the survey
(from 3,000 to 4,000). We will use a
cognitive interview screener with 100
individuals to recruit prospective
interview participants. We estimate that
it will take a screener respondent
approximately 5 minutes (0.08 hours) to
complete the cognitive interview
screener, for a total of 8 hours. We will
conduct cognitive interviews with 18
participants. We estimate that it will
take a participant approximately 1 hour
to complete the interview, for a total of
18 hours. Prior to the administration of
the Health and Diet Survey, the Agency
plans to conduct a pretest to identify
and resolve potential survey
administration problems. We will use a
pretest screener with 2,000 individuals;
we estimate that it will take a
respondent approximately 2 minutes
(0.033 hours) to complete the pretest
screener, for a total of 66 hours. The
pretest will be conducted with 200
participants; we estimate that it will
take a participant 15 minutes (0.25
hours) to complete the pretest, for a total
of 50 hours. We will use a survey
screener to select an eligible adult
VerDate Sep<11>2014
17:47 Jul 17, 2017
Jkt 241001
respondent in each household reached
by landline telephone numbers to
participate in the survey. A total of
40,000 individuals in the 50 states and
the District of Columbia will be
screened by telephone. We estimate that
it will take a respondent 2 minutes
(0.033 hours) to complete the screening,
for a total of 1,320 hours. We estimate
that 4,000 eligible adults will participate
in the survey, each taking 15 minutes
(0.25 hours), for a total of 1,000 hours.
Thus, the total estimated burden is
2,462 hours.
We are requesting this burden for
unplanned surveys so as not to restrict
our ability to gather information on
consumer attitudes, awareness,
knowledge, and behavior regarding
various topics related to health,
nutrition, physical activity, and product
labeling. This ability will help the
Agency identify and respond to
emerging issues in a more timely
manner.
Dated: July 11, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–15001 Filed 7–17–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0598]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Current Good
Manufacturing Practice Regulations for
Type A Medicated Articles
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by August 17,
2017.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0154. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
E:\FR\FM\18JYN1.SGM
18JYN1
Federal Register / Vol. 82, No. 136 / Tuesday, July 18, 2017 / Notices
Ila
S. Mizrachi, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
St., North Bethesda, MD 20852, 301–
796–7726, PRAStaff@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Current Good Manufacturing Practice
Regulations for Type A Medicated
Articles—21 CFR Part 226 OMB Control
Number 0910–0154—Extension
Under section 501 of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act), FDA has the statutory
authority to issue current good
manufacturing practice (cGMP)
regulations for drugs, including Type A
medicated articles. A Type A medicated
article is a feed product containing a
concentrated drug diluted with a feed
carrier substance. A Type A medicated
article is intended solely for use in the
manufacture of another Type A
medicated article or a Type B or Type
C medicated feed. Medicated feeds are
administered to animals for the
prevention, cure, mitigation, or
treatment of disease or for growth
promotion and feed efficiency.
Statutory requirements for cGMPs for
Type A medicated articles have been
codified in part 226 (21 CFR part 226).
Type A medicated articles, which are
not manufactured in accordance with
these regulations, are considered
adulterated under section 501(a)(2)(B) of
the FD&C Act (21 U.S.C. 351(a)(2)(B)).
Under part 226, a manufacturer is
required to establish, maintain, and
retain records for Type A medicated
articles, including records to document
procedures required under the
manufacturing process to assure that
proper quality control is maintained.
Such records would, for example,
contain information concerning receipt
and inventory of drug components,
batch production, laboratory assay
results (i.e., batch and stability testing),
and product distribution.
The required records are used by both
the respondents and FDA. The records
are used by manufacturers of Type A
medicated articles to verify that
appropriate control measures have been
maintained, or that appropriate
corrective actions were taken if the
control measures were not maintained.
Such verification activities are essential
to ensure that the cGMP system is
32835
working as planned. We review the
records during the conduct of periodic
plant inspections. This information is
needed so that we can monitor drug
usage and possible misformulation of
Type A medicated articles. The
information could also prove useful to
us in investigating product defects when
a drug is recalled. In addition, we will
use the cGMP criteria in part 226 to
determine whether or not the systems
used by manufacturers of Type A
medicated articles are adequate to
assure that their medicated articles meet
the requirements of the FD&C Act as to
safety and also meet the article’s
claimed identity, strength, quality, and
purity, as required by section
501(a)(2)(B) of the FD&C Act. The
respondents for Type A medicated
articles are pharmaceutical firms that
manufacture both human and veterinary
drugs, those firms that produce only
veterinary drugs, and commercial feed
mills.
In the Federal Register of October 17,
2016 (81 FR 71513), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. FDA received no comment.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Noumber of
records per
recordkeeper
Number of
recordkeepers
21 CFR section
Total annual
records
Average burden per
recordkeeping
Total hours
226.42, requires records be prepared and maintained for 2 years with respect to components
(drug and non-drug) used in the manufacture of
the medicated premixes.
226.58, requires recordkeeping for establishment
of laboratory controls to ensure that adequate
specifications and test procedures for the drug
components and Type A medicated articles conform to appropriate standards of identity,
strength, quality, and purity.
226.80, requires maintenance of records for packaging and labeling of Type A medicated articles.
226.102, requires maintenance of master-formula
and batch-production records for Type A medicated articles.
226.110, requires maintenance of distribution
records (2 years) for each shipment of Type A
medicated articles for recall purposes.
226.115, requires maintenance of complaint files
for Type A medicated articles for 2 years.
65
260
16,900
0.75 (45 minutes) ......
12,675
65
260
16,900
1.75 ...........................
29,575
65
260
16,900
0.75 (45 minutes) ......
12,675
65
260
16,900
1.75 ...........................
29,575
65
260
16,900
.25 (15 minutes) ........
4,225
65
10
650
.5 (30 minutes) ..........
325
Total ..................................................................
........................
........................
........................
....................................
76, 375
sradovich on DSK3GMQ082PROD with NOTICES
1
There are no capital costs or operating and maintenance costs associated with this collection of information.
We based our estimate of the time
required for record preparation and
maintenance on our communications
with industry. We derived additional
information needed to calculate the total
burden hours (i.e., manufacturing sites,
VerDate Sep<11>2014
17:47 Jul 17, 2017
Jkt 241001
number of Type A medicated articles
being manufactured, etc.) from our
records and experience. The burden has
not changed since the last OMB
approval.
PO 00000
Dated: July 12, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–14996 Filed 7–17–17; 8:45 am]
BILLING CODE 4164–01–P
Frm 00051
Fmt 4703
Sfmt 9990
E:\FR\FM\18JYN1.SGM
18JYN1
Agencies
[Federal Register Volume 82, Number 136 (Tuesday, July 18, 2017)]
[Notices]
[Pages 32834-32835]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0598]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Current Good
Manufacturing Practice Regulations for Type A Medicated Articles
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that a proposed collection of information has been submitted to the
Office of Management and Budget (OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by August
17, 2017.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0154.
Also include the FDA docket number found in brackets in the heading of
this document.
[[Page 32835]]
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A63, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-7726,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Current Good Manufacturing Practice Regulations for Type A Medicated
Articles--21 CFR Part 226 OMB Control Number 0910-0154--Extension
Under section 501 of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act), FDA has the statutory authority to issue current good
manufacturing practice (cGMP) regulations for drugs, including Type A
medicated articles. A Type A medicated article is a feed product
containing a concentrated drug diluted with a feed carrier substance. A
Type A medicated article is intended solely for use in the manufacture
of another Type A medicated article or a Type B or Type C medicated
feed. Medicated feeds are administered to animals for the prevention,
cure, mitigation, or treatment of disease or for growth promotion and
feed efficiency.
Statutory requirements for cGMPs for Type A medicated articles have
been codified in part 226 (21 CFR part 226). Type A medicated articles,
which are not manufactured in accordance with these regulations, are
considered adulterated under section 501(a)(2)(B) of the FD&C Act (21
U.S.C. 351(a)(2)(B)). Under part 226, a manufacturer is required to
establish, maintain, and retain records for Type A medicated articles,
including records to document procedures required under the
manufacturing process to assure that proper quality control is
maintained. Such records would, for example, contain information
concerning receipt and inventory of drug components, batch production,
laboratory assay results (i.e., batch and stability testing), and
product distribution.
The required records are used by both the respondents and FDA. The
records are used by manufacturers of Type A medicated articles to
verify that appropriate control measures have been maintained, or that
appropriate corrective actions were taken if the control measures were
not maintained. Such verification activities are essential to ensure
that the cGMP system is working as planned. We review the records
during the conduct of periodic plant inspections. This information is
needed so that we can monitor drug usage and possible misformulation of
Type A medicated articles. The information could also prove useful to
us in investigating product defects when a drug is recalled. In
addition, we will use the cGMP criteria in part 226 to determine
whether or not the systems used by manufacturers of Type A medicated
articles are adequate to assure that their medicated articles meet the
requirements of the FD&C Act as to safety and also meet the article's
claimed identity, strength, quality, and purity, as required by section
501(a)(2)(B) of the FD&C Act. The respondents for Type A medicated
articles are pharmaceutical firms that manufacture both human and
veterinary drugs, those firms that produce only veterinary drugs, and
commercial feed mills.
In the Federal Register of October 17, 2016 (81 FR 71513), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. FDA received no comment. FDA estimates the
burden of this collection of information as follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Noumber of
21 CFR section Number of records per Total annual Average burden per recordkeeping Total hours
recordkeepers recordkeeper records
--------------------------------------------------------------------------------------------------------------------------------------------------------
226.42, requires records be prepared and 65 260 16,900 0.75 (45 minutes)......................... 12,675
maintained for 2 years with respect to
components (drug and non-drug) used in the
manufacture of the medicated premixes.
226.58, requires recordkeeping for 65 260 16,900 1.75...................................... 29,575
establishment of laboratory controls to
ensure that adequate specifications and
test procedures for the drug components and
Type A medicated articles conform to
appropriate standards of identity,
strength, quality, and purity.
226.80, requires maintenance of records for 65 260 16,900 0.75 (45 minutes)......................... 12,675
packaging and labeling of Type A medicated
articles.
226.102, requires maintenance of master- 65 260 16,900 1.75...................................... 29,575
formula and batch-production records for
Type A medicated articles.
226.110, requires maintenance of 65 260 16,900 .25 (15 minutes).......................... 4,225
distribution records (2 years) for each
shipment of Type A medicated articles for
recall purposes.
226.115, requires maintenance of complaint 65 10 650 .5 (30 minutes)........................... 325
files for Type A medicated articles for 2
years.
-----------------------------------------------------------------------------------------------------------
Total................................... .............. .............. .............. .......................................... 76, 375
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
We based our estimate of the time required for record preparation
and maintenance on our communications with industry. We derived
additional information needed to calculate the total burden hours
(i.e., manufacturing sites, number of Type A medicated articles being
manufactured, etc.) from our records and experience. The burden has not
changed since the last OMB approval.
Dated: July 12, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-14996 Filed 7-17-17; 8:45 am]
BILLING CODE 4164-01-P